SCHEMBL6329036

SCHEMBL6329036

Cc1ccc(S(=O)(=O)c2c(C)[nH]c(/C=C3\C(=O)Nc4ccccc43)c2CCC(=O)O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.67
KDR P35968 12/20 0.67
PDGFRB P09619 12/20 0.67
AURKA O14965 5/20 0.67
FLT1 P17948 3/20 0.67
RET P07949 2/20 0.67
FLT3 P36888 2/20 0.67
MAP4K2 Q12851 2/20 0.67
STK3 Q13188 2/20 0.67
AURKB Q96GD4 2/20 0.67
ZAP70 P43403 2/20 0.67
GAK O14976 1/20 0.67
RPS6KA5 O75582 1/20 0.67
RPS6KA4 O75676 1/20 0.67
LATS1 O95835 1/20 0.67
CSNK2A2 P19784 1/20 0.67
MAP2K2 P36507 1/20 0.67
MAP2K1 Q02750 1/20 0.67
STK4 Q13043 1/20 0.67
MAP2K5 Q13163 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330055 0.95 FGFR1 (0.70) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6326101 0.93 KDR (0.65) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6326117 0.90 FGFR1 (0.60) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6329239 0.89 FGFR1 (0.64) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6326844 0.89 FGFR1 (0.74) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6329246 0.88 FGFR1 (0.69) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6328908 0.88 AURKA (0.68) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6330265 0.88 KDR (0.59) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6327913 0.88 FGFR1 (0.60) FGFR1KDRPDGFRBAURKAFLT1
SCHEMBL6335062 0.88 AURKA (0.64) FGFR1KDRPDGFRBAURKAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US claimed
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors MAP3K20, CDK20, STK10 FGFR1 382/4885KDR 974/4885PDGFRB 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.